Delivery Order SPE2DB22D9311-SPE2DB26FP6WQ
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Boostrix TDAP vaccine syringes (0.5mL) under a firm fixed-price contract. This delivery order, valued at $13,922.86 with an ultimate completion date of July 21, 2025, was issued without a set-aside designation. The award leverages DMS Pharmaceutical Group's position as a critical supplier within the...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $21,878.78 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Boostrix TDAP vaccine in 0.5 mL syringes. The contract, awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, carries no set-aside designation. DMS Pharmaceutical Group will perform this work at its Park Ridge facility and deliver the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $26,720.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on May 16, 2025. The delivery order is for Boostrix TDAP vaccine in 0.5mL syringes, with an ultimate completion date of May 19, 2025. This firm fixed-price delivery order was issued without set-aside designation, leveraging the contractor's established position in the federal pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,988.98 to DMS Pharmaceutical Group Inc. on June 3, 2025, with an ultimate completion date of June 4, 2025. The delivery order is for Boostrix TDAP vaccine syringes in 0.5mL dosages, to be delivered to Park Ridge, Illinois. This contract utilizes a firm fixed-price structure with no set-aside designation. The award represents a single delivery order issued under DMS Pharmaceutical Group's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $5,114.52 to DMS Pharmaceutical Group Inc. for the supply of Boostrix TDAP vaccine in 0.5mL syringes. DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will perform this contract at its facility in Park Ridge. The delivery order was issued on August 7, 2025, with an ultimate completion date of August 8, 2025, and no set-aside designation was...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on September 4, 2025, by the Defense Logistics Agency for the supply of Boostrix TDAP vaccine syringes (0.5ML) with a ceiling value of $18,152.32. This firm fixed-price delivery order, which must be completed by September 5, 2025, represents a routine pharmaceutical supply transaction under DMS Pharmaceutical Group's existing Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, received a delivery order award from the Defense Logistics Agency (DLA) on June 11, 2025, for Boostrix TDAP vaccine syringes in 0.5ml units. The contract is valued at $1,136.56 and carries a firm fixed-price structure with an ultimate completion date of June 12, 2025. This delivery order was issued without a set-aside designation, and performance will take place at the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on August 27, 2025, by the Defense Logistics Agency for the supply of Boostrix TDAP vaccine in 0.5 mL syringes. The contract carries a ceiling value of $17,048.40 and is structured as a firm fixed-price delivery order with an ultimate completion date of August 28, 2025. No set-aside designation was utilized for this award, and the place of...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $3,693.82 to DMS Pharmaceutical Group Inc. for the supply of Boostrix TDAP vaccine in 0.5mL syringes. The contract, effective July 23, 2025, with an ultimate completion date of July 24, 2025, represents a delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $499,999,999 and valid through November 2026. No set-aside designation was applied to this award. The...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $48.5K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This firm fixed-price delivery order was awarded on September 18, 2025, with an ultimate completion date of September 19, 2025, and carries no set-aside designation. The contract will be performed in Park Ridge, Illinois, where the vendor...
- SPE2DB22D9311Indefinite Delivery Contract
- SPE2DB22D9311-SPE2DB26FP6WQDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,061.57 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This firm fixed-price delivery order, issued on October 31, 2025, with an ultimate completion date of November 3, 2025, was awarded without a set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition strategy that establishes multiple regional prime vendor contractors to support the Department of Defense's pharmaceutical supply requirements. DMS Pharmaceutical Group has served as a critical supplier within the federal pharmaceutical supply chain since its SAM registration in 2001, with established performance across numerous delivery orders for diverse pharmaceutical products ranging from routine medications to specialty biologics and vaccines. The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, with a ceiling value of $499,999,999 and a completion date of December 31, 2036, comprises a 30-month base period and three 30-month option periods. This contract authorizes the DLA to issue firm fixed-price delivery orders for comprehensive pharmaceutical and medical consumable products to support military healthcare facilities worldwide, positioning DMS Pharmaceutical Group as a key component of Department of Defense global medical supply operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $11.1k | 10/31/25 |